BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset ...

Bristol Myers Squibb BMY announced data from three studies evaluating CD19-directed CAR T cell therapy Breyanzi (liso-cel) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

Credit: Bristol Myers Squibb. The expanded approval was based on data from the phase 3 TRANSFORM and phase 2 PILOT studies. The Food and Drug Administration (FDA) has approved Breyanzi ® ...

Among the 94 evaluable patients, the overall response rate was 95.7%. The Food and Drug Administration (FDA) has granted accelerated approval to Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best stocks to buy for the next 5 years. On December 15, Goldman Sachs raised the firm’s price target on Bristol-Myers Squibb to $57 from $51, ...

Breyanzi has shown significant efficacy and durable responses in patients with marginal zone lymphoma. Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 ...

In the years since gaining an initial FDA approval for Breyanzi, Bristol Myers Squibb has worked hard to expand the reach of its cell therapy. For the third time in as many months, those efforts have ...

Bristol Myers’ (BMY) CAR T cell therapy Breyanzi (lisocabtagene maraleucel; liso-cel) posted strong growth in the second quarter. Breyanzi is a CD19-directed CAR T cell therapy with a 4-1BB ...

Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had ...

Among patients treated in the third-line plus setting, Breyanzi demonstrated a high overall response rate of 97.1% and a complete response (CR) rate of 94.2%, the study’s primary and key secondary ...